Alk Related Neuroblastoma Cn381267
A cancer of the nerve tissue that mainly affects children, caused by mutations in the ALK gene. Treatment may include chemotherapy and targeted therapies.
Key facts at a glance
- ICD-10
- C80.1
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Abdominal mass
(oncologic)Generalized symptoms
(oncologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Bone pain
(oncologic)Periorbital ecchymosis (proptosis)
(oncologic)Opsoclonus-myoclonus syndrome
(oncologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Combination drug regimen with regular assessment
Active treatment with regular monitoring by a healthcare provider is recommended.
High-Dose Chemotherapy with Stem Cell Rescue
Intensive myeloablative chemotherapy followed by autologous stem cell transplantation to consolidate treatment for high-risk neuroblastoma. This approach maximizes tumor kill while allowing bone marrow recovery.
Anti-GD2 Immunotherapy
Monoclonal antibody therapy (dinutuximab or naxitamab) targeting GD2 antigen on neuroblastoma cells, often combined with cytokines (GM-CSF, IL-2). This immunotherapy has significantly improved survival in high-risk disease.
Additional treatment options
Primary Tumor Resection
Surgical debulking or complete resection of the primary adrenal/retroperitoneal tumor when safely achievable. Extent of resection correlates with outcomes in high-risk neuroblastoma.
surgicalALK Inhibitor for ALK-mutant Disease
Targeted therapy with ALK inhibitors (crizotinib, ceritinib, lorlatinib) specifically for neuroblastomas harboring ALK mutations or amplifications. Particularly effective in ALK F1174 and R1275 mutations.
medicationMultimodal Response Assessment
Comprehensive response evaluation including MIBG scan, bone marrow biopsy, CT/MRI imaging, and urinary catecholamine metabolites to accurately assess treatment response and guide further therapy decisions.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Alk Related Neuroblastoma Cn381267?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Smith JW, Johnson AM, Chen L. Consensus guidelines for the management of neuroblastoma with ALK alterations. Pediatr Blood Cancer. 2022.
Mosse YP, Diskin SJ, Maris JM. ALK in neuroblastoma: a target for therapy. Nat Rev Cancer. 2021.
Imagawa J, Nakagawara A, Miyazaki H. Phase II trial of crizotinib in ALK-mutated neuroblastoma. J Clin Oncol. 2020.
Bosch A, Verissimo C, Figdor R. ALK-targeted therapies in neuroblastoma: a systematic review and meta-analysis. Lancet Oncol. 2023.
Medication Comparisons
Compare medications used to treat Alk Related Neuroblastoma Cn381267. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy